Client Image
click to play video

Investment Manager Monthly Commentary

January 2012

The biotech sector performed strongly during the month mainly due to M&A activity and strong product launches. Dendreon and Gilead were the top contributors to performance, Dendreon reported better than expected results and Gilead performed strongly after takeover of Pharmasset.
Read More… 

Latest Fact Sheet Latest Fact Sheet Latest Annual or Interim Report Latest Annual or Interim Report

Daily Data

At Close 22 Feb 2012

Price:228.00p

NAV:237.26p

Prem/-Disc:-3.90%

Source: Morningstar

Net Asset Value per ordinary share, including income, fully diluted.

Register

To request emailed copies of monthly fact sheets and other relevant information, please register below.